Slides
Page 1
Page 1 Delivering Growth – in Asia and Beyond. DKSH to Acquire NewBridge Pharmaceuticals Establishing a Healthcare Platform in the Middle East and Scaling Up Capabilities October 19, 2026
Page 2
Page 2 Disclaimer This presentation is for information purposes only. It does not constitute an offer to sell, or a solicitation of an offer to buy, any securities of DKSH, and it is not a prospectus within the meaning of the Swiss Financial Services Act (FinSA). It does not constitute a recommendation regarding any investment in DKSH and should not be treated as giving investment advice. The completion of the acquisition of NewBridge Pharmaceuticals (“NewBridge”) is subject to customary closing conditions, including regulatory approvals. There can be no assurance that the transaction will be completed as expected or at all. Certain information on NewBridge in this presentation is based on management information and estimates, as well as financial information which is unaudited and thus is subject to change. This presentation contains alternative performance measures, such as EBITDA, which are not defined under IFRS and may not be comparable to similarly titled measures presented by other companies. They should be read in addition to, and not as a substitute for, measures prepared under IFRS. Market and industry data in this presentation are based on third-party sources and DKSH estimates. Figures have been rounded and may therefore not add up exactly to the totals shown. While this presentation has been prepared by DKSH with due care and based on information it reasonably believes to be accurate, complete and up-to-date on the date hereof, this presentation may be inaccurate or incomplete or contain typographical errors or information that is not up-to-date. DKSH does not assume any liability for relevance, accuracy or completeness of the information included in this presentation. DKSH reserves the right to change, supplement or delete at any time some or all of the information included in this presentation without notice. This presentation may contain certain forward-looking statements relating to DKSH and its business, including, but not limited to, statements regarding DKSH's financial position, business strategy, plans and objectives of management for future operations. Words like "believe", "anticipate", "expect", "project", "estimate", "predict", "intend", "target", "assume", "may", "might", "could", "should", "will" and similar expressions may indicate such forward-looking statements. Forward-looking statements are based on numerous assumptions regarding, among other things, DKSH's present and future business strategies and the environment in which DKSH will operate in the future, some of which are beyond DKSH’s control. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of DKSH to be materially different from those expressed or implied by such statements. Readers of this presentation should therefore not place undue reliance on these statements. In particular, readers should not rely on any forward-looking statements in this presentation in connection with their entering into any contract or forming an investment decision. DKSH disclaims any obligation to update any forward-looking statements. The layout, graphics and other contents of this presentation are protected by copyright law and may not be reproduced or used without DKSH’s prior written consent.
Page 3
Page 3 Speakers Patrik Grande Head, Business Unit Healthcare Ido Wallach Chief Financial Officer Stefan P. Butz Chief Executive Officer
Page 4
Page 4 Agenda 1. Strategic Rationale and Transaction Overview 4. Key Takeaways 3. Financial Impact 2. Introduction to NewBridge and Strategic Fit with DKSH Healthcare 5. Q&A
Page 5
Page 5 Delivering on our Strategy: Accelerating Profitable Growth in Healthcare, in Asia and Beyond 1. Strategic Rationale and Transaction Overview What we said What NewBridge delivers Accelerate more impactful M&A, focused on higher-value businesses Expand beyond Asia Pacific into structurally attractive, fast-growth developing markets Grow commercial outsourcing, a key growth driver of DKSH Healthcare A leading platform for specialty and rare disease medicines in the Middle East and North Africa (MENA), across 14 markets Asia Pacific and MENA on one platform: 31 markets and a single partner of choice for global biopharma companies Higher-value growth: Strengthens commercial outsourcing in a structurally growing region Accretive to the Group’s Net sales growth, Core EBIT margin and earning per share from closing 100% Stake to be acquired USD 390 million Enterprise value, fully debt-funded ~USD 385 million Net sales 2027E High single-digit EBITDA margin 2027E By end of Q1 2027 Subject to customary conditions
Page 6
Page 6 A Large, Wealthy and Growing Healthcare Market1 ~350 million People across NewBridge’s markets ~CHF 3 trillion Combined GDP of NewBridge’s markets ~2.8x Gulf GDP per capita versus the global average 1.7x Growth of the over-65 population in the Gulf versus the global rate USD 6-7 billion Outsourced commercialization market by 2031 NewBridge is a Leading Healthcare Commercialization Platform for Specialty and Rare Disease Medicines in the Region 2. Introduction to NewBridge and Strategic Fit with DKSH Healthcare Geographic FootprintCompany Overview 1 Sources: UN World Population Prospects 2024, IMF World Economic Outlook, World Bank, third-party commercial due diligence Dubai-based commercialization platform focused on innovative medicines across the region Benefiting from regional healthcare growth and increasing demand for commercialization partners Partner of choice with a proven track record and broad, long-standing pharmaceutical relationships Integrated platform spanning market access, medical affairs, sales, and scientific engagement 2010 Established 300+ Employees 14 Markets
Page 7
Page 7 One Integrated Platform to Better Serve our Global Partners 2. Introduction to NewBridge and Strategic Fit with DKSH Healthcare 1 Scaling up from 17 to 31 markets A single commercial partnership spanning Asia Pacific and MENA, with coordinated regional management and local execution One multi-regional commercialization partner 2 Specialty, oncology and rare diseases Complementary expertise in specialty medicines, including oncology, neurology, immunology, gastroenterology, and rare diseases High-value innovative therapies 3 Integrated capabilities offering Bringing together launch excellence, market access, medical affairs, and scientific engagement across regions End-to-end commercialization capabilities 4 Cross-regional growth opportunities A broader platform to support existing partners across new geographies, attract new clients, and accelerate portfolio expansion A platform for future growth Aligned with DKSH Healthcare strategy Focused on higher-value growth segments Commercial Outsourcing Regional partnerships, innovative launches and specialty commercialization Own Brands Development of DKSH’s proprietary healthcare portfolio NewBridge directly strengthens DKSH Healthcare’s Commercial Outsourcing Platform Combining DKSH's established Asia Pacific expertise with NewBridge's MENA capabilities to unlock new opportunities for our healthcare partners
Page 8
Page 8 Accretive to Margin and Earnings per Share 3. Financial Impact Keeping headroom for further M&A and an unchanged progressive dividend policy from closing and accretive to the Group’s Net sales growth and Core EBIT margin Enterprise value USD 390 million For 100% of NewBridge NewBridge Net sales 2027E ~USD 385 million Expected Net sales in 2027 NewBridge EBITDA margin 2027E High single-digit In the higher-value segment of commercial outsourcing Financing Fully debt-funded Accretion EPS accretive Timeline Q1 2027 Closing expected by the end of the first quarter, subject to customary closing conditions, including regulatory approvals Key Figures at a Glance
Page 9
Page 9 Pivotal Step for DKSH Healthcare: Leading Platform, Complementary Fit, Higher-Value Growth, Accretive to EPS 4. Key Takeaways Leading Platform with Long-standing Partnerships • Leading platform for specialty and rare disease medicines in the region, with long -standing global biopharma partnerships and hard-to-replicate capabilities across 14 markets • Net sales of around USD 385 million expected in 2027, with high single-digit EBITDA margin Higher-Value Growth • High-quality commercial outsourcing asset in the higher-margin segment of specialty and rare disease medicines, supported by structural growth in healthcare in the region • Accretive to DKSH’s Net sales growth and Core EBIT margin, strengthening a key growth driver of DKSH Healthcare Financially Disciplined • Enterprise value of USD 390 million, fully debt-funded, keeping headroom for further M&A and an unchanged progressive dividend policy • EPS accretive from closing • Closing expected by the end of the first quarter of 2027, subject to customary closing conditions • Asia Pacific and MENA on one platform: the same commercial outsourcing model, no geographic overlap, and expanding from 17 to 31 markets • Scaled-up capabilities in launch excellence, market access, and medical affairs make DKSH Healthcare a single partner of choice across a broader footprint Full Complementarity Delivering on our strategy to accelerate more impactful M&A into structurally attractive, fast-growth developing markets
Page 10
Page 10 Delivering Growth – in Asia and Beyond.